1
|
Gupta P, Wentland JA, Leal M, Ma D, Roach R, Esparza A, King L, Spilker ME, Bagi C, Winkelmann CT, Giddabasappa A. Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography. Oncotarget 2017; 8:57231-57245. [PMID: 28915667 PMCID: PMC5593638 DOI: 10.18632/oncotarget.19569] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 07/03/2017] [Indexed: 01/26/2023] Open
Abstract
Non-invasive imaging using radiolabels is a common technique used to study the biodistribution of biologics. Due to the limited shelf-life of radiolabels and the requirements of specialized labs, non-invasive optical imaging is an attractive alternative for preclinical studies. Previously, we demonstrated the utility of fluorescence molecular tomography (FMT) an optical imaging modality in evaluating the biodistribution of antibody-drug conjugates. As FMT is a relatively new technology, few fluorophores have been validated for in vivo imaging. The goal of this study was to characterize and determine the utility of near-infrared (NIR) fluorophores for biodistribution studies using interleukin-13 receptor subunit alpha-2 antibody (IL13Rα2-Ab). Eight fluorophores (ex/em: 630/800 nm) with an N-hydroxysuccinimide (NHS) linker were evaluated for Ab conjugation. The resulting antibody-fluorophore (Ab-F) conjugates were evaluated in vitro for degree of conjugation, stability and target-binding, followed by in vivo/ex vivo FMT imaging to determine biodistribution in a xenograft model. The Ab-F conjugates (except Ab-DyLight800) showed good in vitro stability and antigen binding. All Ab-F conjugates (except for Ab-BOD630) resulted in a quantifiable signal in vivo and had similar biodistribution profiles, with peak tumor accumulation between 6 and 24 h post-injection. In vivo/ex vivo FMT imaging showed 17–34% ID/g Ab uptake by the tumor at 96 h. Overall, this is the first study to characterize the biodistribution of an Ab using eight NIR fluorophores. Our results show that 3-dimensional optical imaging is a valuable technology to understand biodistribution and targeting, but a careful selection of the fluorophore for each Ab is warranted.
Collapse
Affiliation(s)
- Parul Gupta
- Global Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA
| | - Jo-Ann Wentland
- Pharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA
| | - Mauricio Leal
- Pharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA
| | - Dangshe Ma
- Oncology Research Unit, Pfizer, Inc., Pearl River, NY, USA.,Current affiliation: Regeneron Pharmaceuticals, Tarrytown, NY, USA
| | - Rachel Roach
- Center for Therapeutic Innovation, Pfizer, Inc., La Jolla, CA, USA
| | | | - Lindsay King
- Pharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA
| | - Mary E Spilker
- Pharmacokinetics and Drug Metabolism, Pfizer, Inc., New York NY, USA
| | - Cedo Bagi
- Global Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA
| | | | - Anand Giddabasappa
- Global Science and Technology, Comparative Medicine, Pfizer, Inc., La Jolla, CA, USA
| |
Collapse
|
2
|
Leal M, Wentland J, Han X, Zhang Y, Rago B, Duriga N, Spriggs F, Kadar E, Song W, McNally J, Shakey Q, Lorello L, Lucas J, Sapra P. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice. Bioconjug Chem 2015; 26:2223-32. [PMID: 26180901 DOI: 10.1021/acs.bioconjchem.5b00205] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The pharmacokinetics of an antibody (huA1)-drug (auristatin microtubule disrupting MMAF) conjugate, targeting 5T4-expressing cells, were characterized during the discovery and development phases in female nu/nu mice and cynomolgus monkeys after a single dose and in S-D rats and cynomolgus monkeys from multidose toxicity studies. Plasma/serum samples were analyzed using an ELISA-based method for antibody and conjugate (ADC) as well as for the released payload using an LC-MS/MS method. In addition, the distribution of the Ab, ADC, and released payload (cys-mcMMAF) was determined in a number of tissues (tumor, lung, liver, kidney, and heart) in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) using similar LBA and LC-MS/MS methods. Tissue distribution studies revealed preferential tumor distribution of cys-mcMMAF and its relative specificity to the 5T4 target containing tissue (tumor). Single dose studies suggests lower CL values at the higher doses in mice, although a linear relationship was seen in cynomolgus monkeys at doses from 0.3 to 10 mg/kg with no evidence of TMDD. Evaluation of DAR (drug-antibody ratio) in cynomolgus monkeys (at 3 mg/kg) indicated that at least half of the payload was still on the ADC 1 to 2 weeks after IV dosing. After multiple doses, the huA1 and conjugate data in rats and monkeys indicate that exposure (AUC) increases with increasing dose in a linear fashion. Systemic exposure (as assessed by Cmax and AUC) of the released payload increased with increasing dose, although exposure was very low and its pharmacokinetics appeared to be formation rate limited. The incidence of ADA was generally low in rats and monkeys. We will discuss cross species comparison, relationships between the Ab, ADC, and released payload exposure after multiple dosing, and insights into the distribution of this ADC with a focus on experimental design as a way to address or bypass apparent obstacles and its integration into predictive models.
Collapse
Affiliation(s)
- Mauricio Leal
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Pearl River, New York 10965, United States
| | - JoAnn Wentland
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Xiaogang Han
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Yanhua Zhang
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Brian Rago
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Nicole Duriga
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover, Massachusetts 01810, United States
| | - Franklin Spriggs
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover, Massachusetts 01810, United States
| | - Eugene Kadar
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Wei Song
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - James McNally
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover, Massachusetts 01810, United States
| | - Quazi Shakey
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover, Massachusetts 01810, United States
| | - Leslie Lorello
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Judy Lucas
- Oncology Research Unit, Pfizer Inc. , Pearl River, New York 10965, United States
| | - Puja Sapra
- Oncology Research Unit, Pfizer Inc. , Pearl River, New York 10965, United States
| |
Collapse
|
3
|
Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, Haddish-Berhane N, Betts A, Leal M. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J 2014; 16:452-63. [PMID: 24578215 DOI: 10.1208/s12248-014-9576-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2013] [Accepted: 01/23/2014] [Indexed: 11/30/2022]
Abstract
The objectives of this investigation were as follows: (a) to validate a mechanism-based pharmacokinetic (PK) model of ADC for its ability to a priori predict tumor concentrations of ADC and released payload, using anti-5T4 ADC A1mcMMAF, and (b) to analyze the PK model to find out main pathways and parameters model outputs are most sensitive to. Experiential data containing biomeasures, and plasma and tumor concentrations of ADC and payload, following A1mcMMAF administration in two different xenografts, were used to build and validate the model. The model performed reasonably well in terms of a priori predicting tumor exposure of total antibody, ADC, and released payload, and the exposure of released payload in plasma. Model predictions were within two fold of the observed exposures. Pathway analysis and local sensitivity analysis were conducted to investigate main pathways and set of parameters the model outputs are most sensitive to. It was discovered that payload dissociation from ADC and tumor size were important determinants of plasma and tumor payload exposure. It was also found that the sensitivity of the model output to certain parameters is dose-dependent, suggesting caution before generalizing the results from the sensitivity analysis. Model analysis also revealed the importance of understanding and quantifying the processes responsible for ADC and payload disposition within tumor cell, as tumor concentrations were sensitive to these parameters. Proposed ADC PK model provides a useful tool for a priori predicting tumor payload concentrations of novel ADCs preclinically, and possibly translating them to the clinic.
Collapse
Affiliation(s)
- Dhaval K Shah
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 455 Kapoor Hall, Buffalo, New York, 14214, USA,
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Reed-Hagen AE, Tsuchiya M, Shimada K, Wentland JA, Obach RS. Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites. Biopharm Drug Dispos 1999; 20:429-39. [PMID: 10951432 DOI: 10.1002/1099-081x(199912)20:9<429::aid-bdd209>3.0.co;2-d] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The pharmacokinetics of ezlopitant were determined in the rat, gerbil, guinea pig, ferret, dog and monkey after intravenous and oral administration. In general, ezlopitant is marked by high clearance values that approach or exceed hepatic blood flow values, moderate to high values for steady-state volume of distribution (3. 9-28 L/kg), and terminal phase half-life values ranging from 0.6 h in the guinea pig to 7.7 h in the rat. Oral bioavailability ranged from <0.2% (guinea pig) to 28% (dog). Data from portal vein cannulated dogs suggested that 37% of an oral dose of ezlopitant enters the portal vein as an unchanged drug in this species. Ezlopitant is metabolized to two pharmacologically active metabolites, an alkene (CJ-12 458) and a benzyl alcohol (CJ-12 764). After administration of the parent compound, CJ-12 764 was found in greater abundance than CJ-12 458 in all species examined. Ezlopitant and CJ-12 458 were highly protein bound in plasma (or serum), whereas the protein binding of CJ-12 764 was somewhat lower. Measurement of the kinetics of ezlopitant, CJ-12 458 and CJ-12 764 in the cerebrospinal fluid (CSF) of dogs demonstrated that all three compounds can partition into the CSF, and thereby, be capable of contributing to centrally mediated pharmacological effects. Thus, these data suggest that the pharmacological activity exhibited by ezlopitant in preclinical species in vivo is likely a result of the parent compound plus the active metabolites. Furthermore, the contributions of ezlopitant and the active metabolites to pharmacological activity probably varies with the identity of the model species, as well as the dose and route of ezlopitant administration.
Collapse
Affiliation(s)
- A E Reed-Hagen
- Drug Metabolism Department, Central Research, Pfizer, Inc., Groton, CT 06340, USA
| | | | | | | | | |
Collapse
|